Kornimate/medical-research-clean huggingface dataset:
interstitial lung disease associated

Conditions: Interstitial Lung Disease

Summary: this single-center, retrospective cohort study was conducted to determine whether anca-ild spectrum share the same clinical manifestations and outcome with ctd feature disease spectrum.

we retrospectively reviewed patients who had been diagnosed with interstitial pneumonia during outpatient or hospitalization at peking union medical college hospital (pumch) between january 2012 and december 2021. 1. baseline data collection: 1. baseline information at the time of initial diagnosis was obtained, and the following items were analyzed: demographic information (age, gender), clinical course, clinical symptoms and signs, laboratory findings \[routine blood, erythrocyte sedimentation rate (esr), hypersensitivity c-reactive protein (hs-crp), rheumatoid factor (rf) and serologic autoantibodies\], pulmonary function tests (pfts), and chest hrct scans. 2. mpo-anca and pr3-anca titers were measured by elisa. 3. chest hrct images were evaluated by at least two pulmonologists and radiologists. the hrct scans were analyzed for the following characteristics: ground-glass opacities, reticular patterns, honeycombing, traction bronchiectasis. 4. spirometry was performed according to standardized guidelines. pfts results were expressed as percentages of the predicted values, thereby correcting for age, gender and bodyweight. 2. treatment was defined as the use of corticosteroids ≥ 10mg/d, azathioprine, cyclophosphamide, mycophenolate mofetil, methotrexate, or rituximab. follow-up was up to the time of patient's last visit or time of death, and the outcomes were defined as death from all causes. 3. outcome

Eligibility criteria:
inclusion criteria: * males and females * aged from 18 to 85 years with informed consent * have a diagnosis of ild based on clinical symptoms and radiologic features, with or without histopathologic results exclusion criteria: * ild induced by drug, environment, or occupational exposure * hypersensitivity pneumonitis and sarcoidosis

Keywords: interstitial lung disease, anca, ctd, ipaf, iip
botulinum toxin type a (dysport) associated with rehabilitation treatment in patients with primary myofascial pain syndrome

Conditions: Myofascial Pain Syndromes

Summary: the main purpose of this study is to determine the effectiveness and safety of one dose of botulinum toxin type a (dysport) associated with rehabilitation treatment on pain control in patients with a type of back pain called primary myofascial pain syndrome.


Eligibility criteria:
inclusion criteria: * patients with primary myofascial pain syndrome of cervical and dorsal localization, less than two years of length, who must have been diagnosed with the evidence of "trigger points" in which conventional treatment with oral analgesia, rehabilitation and local anesthesia has not been clinically successful for more than 15 days. * punctuation of 4cm or more in a 10cm visual analog scale. * previous positive response (self-limited reduction -less than 15 days- of pain) after an anaesthetic infiltration in the trigger point. exclusion criteria: * patients diagnosed with fibromyalgia or with a spread pain. * patients having received previously botulinum toxin. * patients having received anesthetic injections at the trigger points within the month before the visit. * patients having received corticosteroids injections at the trigger points within three months before the selection visit.

Keywords: dysport botulinum toxin a myofascial pain syndrome
effects of acupuncture for senile pruritus

Conditions: Senile Pruritus

Summary: senile pruritus (sp), characterized by idiopathic itching in individuals aged 60 years and older without primary skin lesions, significantly impacts sleep and quality of life. effective alternative treatments are needed. acupuncture has been suggested as a potential intervention to alleviate itching; however, its role in managing sp remains uncertain. this study aims to evaluate the effects and safety of acupuncture for sp. this single-centre, parallel, two-arm, randomized, sham-controlled trial will enroll 108 patients diagnosed with sp in a 1:1 ratio to either the acupuncture or sham acupuncture group. participants, outcome assessors, and the statistician will be blinded. treatment will consist of 18 sessions over 6 weeks. the primary outcome is change from baseline in the numerical rating scale (nrs) score for average itching severity at week 6, assessed weekly via weekly diary of pruritus assessment. secondary outcomes include changes in nrs score for maximum itching severity, daily episodes of itching, itchy area of body surface, overall dry skin score (ods), the dermatology life quality index (dlqi), the pittsburgh sleep quality index (psqi), the hospital anxiety and depression scale (hads), and patient global impression of change (pgic). adverse events will be monitored throughout the study period. the intention-to-treat (itt) population will include participants who complete baseline assessments and receive at least one treatment session.


Eligibility criteria:
inclusion criteria: participants aged between 60 and 80 years who meet diagnostic criteria for sp, with an average severity score of itching in the past week of ≥4 points on the numerical rating scale (nrs), and who voluntarily provide written informed consent are eligible for inclusion. exclusion criteria: participants will be excluded if they meet any of the following criteria: 1. severe skin damage or infection; 2. severe underlying diseases including cardiovascular diseases, hepatobiliary diseases, kidney diseases, hematologic diseases, autoimmune diseases, infectious diseases, severe malnutrition, or malignancies; 3. mental illness, cognitive dysfunction, or language disorders; 4. received acupuncture therapy for pruritus within the past month; 5. have a history of drug abuse.

Keywords: acupuncture senile pruritus randomized controlled trial
vildagliptin compared to glimepiride in combination with metformin in patients with type 2 diabetes

Conditions: Diabetes Mellitus, Type 2

Summary: many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. the purpose of this study is to assess the long term safety and effectiveness of vildagliptin, an unapproved drug, compared to that of glimepiride in lowering overall blood glucose levels when added to metformin in people with type 2 diabetes not at target blood glucose levels on metformin alone.


Eligibility criteria:
inclusion criteria: * on a stable dose of metformin as defined by the protocol * body mass index (bmi) in the range 22-45 * blood glucose criteria must be met exclusion criteria: * pregnancy or lactation * type 1 diabetes * evidence of significant diabetic complications * evidence of serious cardiovascular complications * laboratory value abnormalities as defined by the protocol * other protocol-defined exclusion criteria may apply

Keywords: type 2 diabetes vildagliptin
evaluation of the effect of streptococcus salivarius k12 probiotic in the treatment of periodontitis

Conditions: Periodontitis Stage III; Probiotic

Summary: aims: the use of oral probiotics as an adjunct to the treatment of periodontal diseases is known to be beneficial in antagonizing pathogenic microflora and regulating the host immune response. the aim of this clinical study was to evaluate the clinical, microbiologic and biochemical effect of streptococcus salivarius (s. salivarius) k12 probiotic tablet as an adjunct to scaling and root planing (srp) treatment in stage 3 periodontitis patients. methods: the study included 30 systemically healthy stage 3 periodontitis patients. after non-surgical periodontal treatment, participants were randomly assigned to the test (srp+probiotic, n=15) or control (srp, n=15) group. patients in the test group used probiotic tablets once daily for 30 days. clinical (plaque index (pi), gingival index (gi), bleeding on probing (bop), probing depth (pd), clinical attachment level (cal)), microbiological (porphyromonas gingivalis, treponema denticola, tannerella forsythia, prevotella intermedia, aggregatibacter actinomycetemcomitans, fusobacterium nucleatum) and biochemical (il-6, il-8, il-10) measurements were performed at baseline (before srp), 30. and 90th days. data were analyzed statistically. keywords: microbiology, periodontitis, probiotics, cytokines


Eligibility criteria:
inclusion criteria: * male or female aged 18-60 years, * no systemic disease, * no periodontal treatment in the last 6 months, * no antibiotic therapy in the last 6 months, * diagnosed with stage 3 periodontitis according to the 2017 periodontal disease classification exclusion criteria: * periodontal treatment within sixteen months, * smoking, * patients with systemic health problems such as diabetes, rheumatoid arthritis, neurological diseases, lung and kidney diseases, * pregnancy or lactation, * acute oral lesions or necrotizing ulcerative periodontitis.

Keywords: microbiology, periodontitis, probiotics, cytokines
analysing the psychosocial effects of covid-19 pandemic on dental professionals using the turkish version of the fear of covid-19 and coronavirus anxiety scales

Conditions: COVID-19 Pandemic

Summary: the aims of this study were to (i) assess fear and anxiety of covid-19 in a turkish sample dental professionals using the turkish fcv-19s and cas; (ii) explore factors associated with fcv-19s and cas; and (iii) examine the psychometric properties of the turkish fcv-19s and cas.

this cross-sectional study was conducted between october, 16 to 23, 2020 by sending an online survey questionnaire working in public and university hospitals, including general dentists or specialists. the tool utilized for data collection was a designed online google forms questionnaire. this survey was implemented by using a questionnaire that included socio-demographic data (age range, gender, marital status, systemic disease, professional area, years of clinical experience, number of patients treated daily, smoking status, alcohol consumption, vs), epidemic-related questions and scales measuring the fear and anxiety levels of the participants. fear of covid-19 scale is an unidimensional scale seven-item scale assessing anxiety regarding covid-19 developed by ahorsu et al. items are rated on a 5-item likert scale from 1 (strongly disagree) to 5 (strongly agree) with scores ranging from 7 to 35. a higher score of the fcv-19s represents a greater level of fear. in the study, the bi-factor model and two-factor model consisting of the "emotional response" factor (items 1, 2, 4, and 5) and "physiological response" factor (items 3, 6, and 7) were used. coronavirus anxiety scale is an unidimensional tool that assesses the physiological reactions anxiety related to the covid-19 pandemic. participants were asked to rate 5 items on a 5-point likert-type scale, from 0 (not at all) to 4 (nearly every day over the last 2 weeks).

Eligibility criteria:
inclusion criteria: * dental professionals working in public hospitals * dental professionals working in university hospitals exclusion criteria: * dental professionals working in private clinics

Keywords: fear of covid-19 coronavirus anxiety scale covid-19 dental professionals psychosocial effects
open-label study of oxycodone/apap to treat post-operative pain following arthroscopic knee surgery

Conditions: Disorder of Knee

Summary: this is a pilot trial using this product in patients for the management of pain after outpatient arthroscopic knee surgery. this is an open-label study and the two active ingredients are well known pharmacologic entities.

the objective of this single center is to evaluate the safety and efficacy of oxycodone extended release (mnk-795) in postoperative pain following common musculoskeletal surgical procedures. knee surgery being the most common surgery performed in the us, the investigators chose the model. the investigators also want to look at the flexible-dosing and titration which is the common way pain managed by clinicians. this is an open-label study of mnk 795 to be described in the procedures section. primary endpoint: • change in pain from baseline (before taking the first dose of study medication) measured on nrs secondary endpoints: * patient/investigator global assessment of treatment satisfaction * safety evaluation with adverse event monitoring

Eligibility criteria:
inclusion criteria: 1. individuals aged 18-75 who underwent an orthopedic outpatient surgical procedure of their knee 2. read and understand english and comprehend the procedures associated with participating in a clinical trial. 3. signed an irb approved consent form and hipaa authorization 4. patients with a pain intensity score of 4 or above on the 0-10 numerical rating scale (0 is no pain, 10 is the worst pain imaginable) exclusion criteria: 1. participants in any other clinical trial in the last 30 days or currently enrolled in a clinical trial 2. allergy to oxycodone or acetaminophen. 3. uncontrolled pain or other pain conditions that may interfere with evaluation 4. pregnant women 5. women who are trying to become pregnant 6. women who are breastfeeding 7. patient who is deemed to be medically unstable by the principal investigator 8. history of alcohol, opioid or substance abuse in the last 2 yrs 9. history of sleep apnea that requires cpap 10. history of serious respiratory illness 11. history of gastric bypass 12. prior use of opiates at doses higher than 90mg morphine equivalent dosing 13. will limit the study medication to 4 tab at each dosing and to total dose of 8 tab for 24 hrs. subjects needing doses higher than that, based on their current opioid dose, will not be enrolled or discontinued

Keywords: knee post-operative pain xartemis
stereotactic radiosurgery in treating patients with stage i or stage ii non-small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. purpose: this phase i trial is studying the side effects and best dose of stereotactic radiosurgery in treating patients with stage i or stage ii non-small cell lung cancer.

objectives: * to establish the maximum tolerated dose of cyberknife® hypofractionated stereotactic radiosurgery in patients with medically inoperable, stage i or ii non-small cell lung cancer. * to establish the relationship between positron emission tomography (pet) response and local control and survival using fludeoxyglucose f 18 pet/ct imaging before treatment and at 1, 3, 6, and 12 months after treatment. outline: patients undergo placement of 3 gold fiducial markers by ct-guidance or bronchoscopy. patients then undergo cyberknife® hypofractionated stereotactic radiosurgery over 45-120 minutes twice weekly for 2 weeks. patients undergo fludeoxyglucose f 18 pet/ct scan at baseline and at 1, 3, 6, and 12 months after completion of treatment. after completion of study treatment, patients are followed periodically for up to 4 years.

Eligibility criteria:
inclusion criteria: disease characteristics: * histologically confirmed non-small cell lung cancer * stage i or ii disease (t1-3, n0, m0) * t2 or t3 tumor ≤ 5 cm * no t3 tumors involving the central chest or mediastinum (only chest wall involvement allowed) * tumor deemed technically resectable, in the opinion of an experienced thoracic surgeon, and patient deemed "medically inoperable" * patients with fluorodeoxyglucose (fdg)-avidity in mediastinal lymph nodes are eligible provided they are able to undergo mediastinoscopy to confirm n0 status patient characteristics: * eastern cooperative oncology group (ecog) performance status 0-2 * not pregnant or nursing * fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment exclusion criteria: * no history of contrast allergy * no psychological issues that would preclude the completion of study treatment prior concurrent therapy: * no prior radiotherapy or chemotherapy * no suspected nodal metastasis that cannot be falsified by mediastinoscopy (i.e., hilar or mediastinal nodes that are either fludeoxyglucose f 18 \[fdg\]-avid or measure \> 1 cm in short axis diameter on ct scan) * no tumor within or touching the proximal bronchial tree, defined as a volume of 2 cm in all directions around the proximal bronchial tree (carina, right and left main stem bronchi, right and left upper lobe bronchi, bronchus intermedius, right middle lobe bronchus, lingular bronchus, right and left lower lobe bronchi)

Keywords: stage i non-small cell lung cancer stage ii non-small cell lung cancer
different surgical approaches in patients of early-stage cervical cancer

Conditions: Uterine Cervical Neoplasm; Laparotomy; Laparoscopy; Survival; Mortality; Morbidity; Quality of Life; Pelvic Floor Disorders; Cost-Benefit Analysis

Summary: this multi-center, randomized controlled study aims to compare the survival outcomes (including overall survival, progression-free survival and disease-free survival between chinese uterine cervical patients receiving different surgical routes (laparotomy and laparoscopy) for radical hysterectomy or trachelectomy, which is the primary study objective. all patients with uterine cervical cancer of figo stage ia1 (with lymphovascular space invasion), ia2 and ib1 will be included and randomized into two groups: laparotomy and laparoscopy groups for radical hysterectomy or trachelectomy. secondary study objectives include: patterns of recurrence, treatment-associated morbidity (6 months from surgery), cost-effectiveness, pelvic floor function, and quality of life.


Eligibility criteria:
inclusion criteria: * confirmed primary adenocarcinoma, squamous cell carcinoma or adenosquamous carcinoma of the uterine cervix * figo stage ia1 (with lymphovascular space invasion), ia2 or ib1 * type ii or iii radical hysterectomy or trachelectomy * performance status of ecog 0-1 * aged 18 years or older * signed an approved informed consents exclusion criteria: * not satisfying any of the inclusion criteria
a study of psma adc in subjects with metastatic castration-resistant prostate cancer (mcrpc)

Conditions: Prostate Cancer

Summary: psma adc 2301 is a phase 2, open-label, study to assess the anti-tumor activity and tolerability of prostate specific membrane antigen antibody drug conjugate (psma adc) in two groups of subjects with metastatic castration-resistant prostate cancer (mcrpc). one group comprises subjects who must have received at least one taxane-containing chemotherapy regimen (e.g. docetaxel, cabazitaxel). the second group comprises subjects who are cytotoxic chemotherapy-naïve. subjects who are cytotoxic chemotherapy-naïve must have received and progressed on-, be ineligible for, refused, have an intolerance to-, or not have access to radium-223. both groups of subjects must also have received and progressed on abiraterone acetate and/or enzalutamide. if a subject is unable to receive abiraterone acetate and/or enzalutamide, sponsor approval is required for participation in the study. subjects will receive up to eight doses of psma adc approximately once every three weeks.


Eligibility criteria:
inclusion criteria: 1. a diagnosis of metastatic castration-resistant prostate cancer. 2. a) prior history of treatment with at least one taxane-containing chemotherapy regimen (e.g. docetaxel, cabazitaxel). if a subject has received more than two cytotoxic chemotherapy regimens, sponsor approval is required for study participation. or b) no prior history of treatment with a cytotoxic chemotherapy regimen. 3. must have received and progressed on abiraterone acetate and/or enzalutamide. if subject is unable to receive abiraterone acetate and/or enzalutamide, sponsor approval is required for participation in the study. 4. eastern cooperative oncology group (ecog) performance status of 0, 1, or 2. 5. life expectancy ≥ six months. 6. cytotoxic chemotherapy-naïve subjects only must have received and progressed on-, be ineligible for, refused, have an intolerance to-, or not have access to radium-223. exclusion criteria: 1. treatment within 30 days prior to first dose of study drug of the following: * external radiation therapy * radiopharmaceuticals * cytotoxic chemotherapy * treatment with an investigational agent 2. clinically significant cardiac disease or severe debilitating pulmonary disease 3. an acute infection requiring ongoing antibiotic therapy 4. any prior treatment with psma adc or other therapies targeting psma, or other antibody drug conjugate (adc) products that contain monomethyl auristatin e (mmae) (e.g., brentuximab vedotin, glembatumumab vedotin, asg-5me, rg7450) unless approved by sponsor. 5. history of drug and/or alcohol abuse 6. history of pancreatitis
the effect of music on pain and anxiety during diagnostic outpatient hysteroscopy in postmenopausal women

Conditions: Hysteroscopy

Summary: this study aims to demonstrate the value of music in diagnostic outpatient hysteroscopy on patients' level of pain and anxiety in postmenopausal women

this study aims to demonstrate the value of music in diagnostic outpatient hysteroscopy on patients' levels of pain and anxiety in postmenopausal women.

Eligibility criteria:
inclusion criteria: * menopausal patients with an indication for ofﬁce hysteroscopy (postmenopausal bleeding or abnormal ultrasound ﬁndings) exclusion criteria: patients with cervical pathology retroverted uterus (detected by transvaginal ultrasound) previous cervical surgery patients with severe vaginal bleeding
provider and peer delivered youth smoking intervention

Conditions: Tobacco Dependence

Summary: the purpose of this study was to determine whether a pediatric practice-based smoking prevention and cessation intervention increases abstinence rates among adolescents.

the majority of adolescent smokers are interested in quitting and have attempted to stop with limited success. a recent review of cessation trials for adolescents has concluded that there are no proven programs to help teens stop smoking, but suggested interventions based on cognitive behavioral therapy and sensitive to stages of change appear promising. the american academy of pediatrics suggests that pediatricians are well-positioned to intervene with adolescent smokers, as well as with nonsmokers to prevent initiation. a comprehensive, practice-based smoking prevention and cessation intervention for adolescents delivered by pediatric providers and peer counselors in the context of routine care has the potential for assisting nonsmoking adolescents in remaining smoke-free and smoking adolescents to quit.

Eligibility criteria:
inclusion criteria: * aged 13 to 17, regardless of smoking status * scheduled for routine or acute care office visit * parental consent and youth assent exclusion criteria: * unable to complete study requirements

Keywords: pediatric practice smoking cessation smoking prevention adolescents